(CLB) Core Laboratories - Overview
Sector: Energy | Industry: Oil & Gas Equipment & Services | Exchange: NYSE (USA) | Market Cap: 670m USD | Total Return: 25.2% in 12m
Avg Turnover: 6.64M
EPS Trend: -49.1%
Qual. Beats: -1
Rev. Trend: 83.4%
Qual. Beats: 0
Warnings
Choppy Below Avwap Earnings
Tailwinds
No distinct edge detected
Core Laboratories Inc. (CLB) specializes in reservoir description and production enhancement services for the global oil and gas industry. The company operates through two primary segments: Reservoir Description, which focuses on the laboratory analysis of rock and fluid samples, and Production Enhancement, which provides technologies for well completions, perforations, and stimulations. Beyond traditional fossil fuel services, the firm supports carbon capture, utilization, and storage (CCUS) and geothermal energy projects.
The business model is primarily service-oriented and asset-light compared to heavy equipment providers, as it relies on proprietary analytical data to help clients maximize recovery rates from existing reservoirs. In the Oil & Gas Equipment & Services sector, companies like Core Laboratories are often sensitive to exploration and production (E&P) capital expenditures, which fluctuate based on global commodity prices and rig counts. The company’s focus on reservoir management often results in more stable demand during the production phase of a wells lifecycle compared to the initial drilling phase.
Investors looking for deeper insights into these operational trends may find ValueRay to be a useful tool for further analysis. Founded in 1936 and headquartered in Houston, Texas, Core Laboratories maintains a global footprint, marketing its technical solutions through direct sales and specialized industry distributors.
- Global upstream capital expenditure cycles dictate demand for reservoir characterization services
- International and offshore project expansion drives high-margin reservoir description revenue
- Transition to carbon capture and geothermal projects provides long-term revenue diversification
- Crude oil price volatility impacts client spending on production enhancement technologies
- Adoption of advanced completion diagnostics influences market share in unconventional shale plays
| Net Income: 29.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -4.21 > 1.0 |
| NWC/Revenue: 20.89% < 20% (prev 24.15%; Δ -3.25% < -1%) |
| CFO/TA 0.06 > 3% & CFO 35.1m > Net Income 29.0m |
| Net Debt (156.5m) to EBITDA (72.3m): 2.16 < 3 |
| Current Ratio: 2.05 > 1.5 & < 3 |
| Outstanding Shares: last quarter (46.1m) vs 12m ago -1.50% < -2% |
| Gross Margin: 17.84% > 18% (prev 0.17%; Δ 1.77k% > 0.5%) |
| Asset Turnover: 88.99% > 50% (prev 87.54%; Δ 1.46% > 0%) |
| Interest Coverage Ratio: 4.96 > 6 (EBITDA TTM 72.3m / Interest Expense TTM 10.9m) |
| A: 0.19 (Total Current Assets 214.4m - Total Current Liabilities 104.7m) / Total Assets 587.7m |
| B: 0.29 (Retained Earnings 171.4m / Total Assets 587.7m) |
| C: 0.09 (EBIT TTM 53.9m / Avg Total Assets 589.6m) |
| D: 0.55 (Book Value of Equity 171.4m / Total Liabilities 312.6m) |
| Altman-Z'' = 3.36 = A |
| DSRI: 0.82 (Receivables 108.3m/131.0m, Revenue 524.7m/517.8m) |
| GMI: 0.95 (GM 17.84% / 16.91%) |
| AQI: 1.00 (AQ_t 0.35 / AQ_t-1 0.35) |
| SGI: 1.01 (Revenue 524.7m / 517.8m) |
| TATA: -0.01 (NI 29.0m - CFO 35.1m) / TA 587.7m) |
| Beneish M = -3.22 (Cap -4..+1) = AA |
As of May 28, 2026, the stock is trading at USD 14.02 with a total of 366,961 shares traded.
Over the past week, the price has changed by +2.19%,
over one month by -18.85%,
over three months by -20.23% and
over the past year by +25.21%.
Core Laboratories has received a consensus analysts rating of 3.00. Therefore, it is recommended to hold CLB.
- StrongBuy: 0
- Buy: 1
- Hold: 3
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 16.3 | 16.5% |
P/E Trailing = 23.8361
P/E Forward = 19.7628
P/S = 1.2773
P/B = 2.4378
P/EG = 1.6717
Revenue TTM = 524.7m USD
EBIT TTM = 53.9m USD
EBITDA TTM = 72.3m USD
Long Term Debt = 114.5m USD (from longTermDebt, last quarter)
Short Term Debt = 11.5m USD (from shortTermDebt, last fiscal year)
Debt = 179.3m USD (corrected: LT Debt 114.5m + ST Debt 11.5m) + Leases 53.4m
Net Debt = 156.5m USD (calculated: Debt 179.3m - CCE 22.8m)
Enterprise Value = 826.7m USD (670.2m + Debt 179.3m - CCE 22.8m)
Interest Coverage Ratio = 4.96 (Ebit TTM 53.9m / Interest Expense TTM 10.9m)
EV/FCF = 43.65x (Enterprise Value 826.7m / FCF TTM 18.9m)
FCF Yield = 2.29% (FCF TTM 18.9m / Enterprise Value 826.7m)
FCF Margin = 3.61% (FCF TTM 18.9m / Revenue TTM 524.7m)
Net Margin = 5.53% (Net Income TTM 29.0m / Revenue TTM 524.7m)
Gross Margin = 17.84% ((Revenue TTM 524.7m - Cost of Revenue TTM 431.1m) / Revenue TTM)
Gross Margin QoQ = 16.19% (prev 18.13%)
Tobins Q-Ratio = 1.41 (Enterprise Value 826.7m / Total Assets 587.7m)
Interest Expense / Debt = 6.06% (Interest Expense 10.9m / Debt 179.3m)
Taxrate = 33.78% (15.5m / 45.9m)
NOPAT = 35.7m (EBIT 53.9m * (1 - 33.78%))
Current Ratio = 2.05 (Total Current Assets 214.4m / Total Current Liabilities 104.7m)
Debt / Equity = 0.65 (Debt 179.3m / totalStockholderEquity, last quarter 275.1m)
Debt / EBITDA = 2.16 (Net Debt 156.5m / EBITDA 72.3m)
Debt / FCF = 8.26 (Net Debt 156.5m / FCF TTM 18.9m)
Total Stockholder Equity = 271.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 4.92% (Net Income 29.0m / Total Assets 587.7m)
RoE = 10.68% (Net Income TTM 29.0m / Total Stockholder Equity 271.9m)
RoCE = 13.95% (EBIT 53.9m / Capital Employed (Equity 271.9m + L.T.Debt 114.5m))
RoIC = 7.57% (NOPAT 35.7m / Invested Capital 471.6m)
WACC = 8.46% (E(670.2m)/V(849.5m) * Re(9.65%) + D(179.3m)/V(849.5m) * Rd(6.06%) * (1-Tc(0.34)))
Discount Rate = 9.65% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -51.11 | Cagr: -1.40%
[DCF] Terminal Value 72.69% ; FCFF base≈29.0m ; Y1≈25.4m ; Y5≈20.5m
[DCF] Fair Price = 3.62 (EV 323.4m - Net Debt 156.5m = Equity 166.9m / Shares 46.1m; r=8.46% [WACC]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -49.08 | EPS CAGR: -3.49% | SUE: -2.97 | # QB: -1
Revenue Correlation: 83.38 | Revenue CAGR: 1.14% | SUE: -0.81 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.09 | Chg30d=+0.00% | Revisions=+0% | Analysts=1
EPS next Quarter (2026-09-30): EPS=0.18 | Chg30d=-10.00% | Revisions=-33% | Analysts=1
EPS current Year (2026-12-31): EPS=0.54 | Chg30d=-5.26% | Revisions=-20% | GrowthEPS=-28.0% | GrowthRev=-1.1%
EPS next Year (2027-12-31): EPS=0.85 | Chg30d=-1.16% | Revisions=-20% | GrowthEPS=+58.3% | GrowthRev=+5.2%
[Analyst] Revisions Ratio: -33%